^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD28 agonist

    Related drugs:
    3d
    Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=400, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    |
    alveltamig (ZG006)
    10d
    This Study is Designed to Characterize the Safety, Tolerability, and Anti-tumor Activity of MDX2003 in Patients With Different Types of Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Not yet recruiting, ModeX Therapeutics, An OPKO Health Company
    New P1/2 trial
    1m
    A novel B7-H4/CD3/CD28 trispecific antibody with the SpyTag-SpyCatcher technology suppresses the growth of colorectal cancer. (PubMed, Int Immunopharmacol)
    Furthermore, SpyCatcher-SpyTag technology was introduced to combine the intact B7-H4 antibody with the anti-CD3/CD28 antibody, which are elements of the CD38 × CD28 × CD3 (SAR442257) TsAb, to create a new TsAb named TsAb-B7-H4...Moreover, TsAb-B7-H4 did not induce the infammatory cytokines which produced by human PBMCs. Consequently, we successfully engineered TsAb-B7-H4 which showed antitumor efficacy in CRC.
    Journal • IO biomarker
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    SAR442257
    1m
    RNDO-564-001: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 (clinicaltrials.gov)
    P1, N=149, Recruiting, Rondo Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab)
    2ms
    RNDO-564-001: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 (clinicaltrials.gov)
    P1, N=149, Not yet recruiting, Rondo Therapeutics
    New P1 trial
    |
    Keytruda (pembrolizumab)
    2ms
    R5678-ONC-1879: A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors (clinicaltrials.gov)
    P1/2, N=345, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jul 2026 --> Nov 2027 | Trial primary completion date: Aug 2025 --> Nov 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Libtayo (cemiplimab-rwlc) • nezastomig (REGN5678)
    2ms
    A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=250, Recruiting, Janssen Research & Development, LLC | N=130 --> 250
    Enrollment change
    |
    pasritamig (JNJ-8343)
    2ms
    A Study of CC312 for Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=6, Recruiting, CytoCares Inc
    New P1 trial
    2ms
    Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=44, Recruiting, CytoCares Inc | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial primary completion date
    |
    CD19 positive
    3ms
    Safety and Efficacy Study of CC312 for Moderate to Severe SLE (clinicaltrials.gov)
    P1, N=32, Recruiting, CytoCares Inc
    New P1 trial
    3ms
    A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC (clinicaltrials.gov)
    P1, N=60, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Libtayo (cemiplimab-rwlc) • nezastomig (REGN5678)
    3ms
    A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Regeneron Pharmaceuticals
    New P2 trial
    |
    ubamatamab (REGN4018) • Kevzara (sarilumab)